Clinical trials: Musculoskeletal Cancers
Hip Replacement, Primary, Secondary or Post-traumatic Osteoarthrosis
Observational Study to Evaluate Long-Term Outcome in Hip Arthroplasty
This long-term outcomes study is designed to collect safety and efficacy data on designated, commercially available, hip arthroplasty products.
- Conditions
- Hip Replacement, Primary, Secondary or Post-traumatic Osteoarthrosis, Femur Head Necrosis, Congenital Dislocations
- Trial name
- NCT02230826
- Where
- 13 sites in France
- Volunteers
- 2,500 people
- Sponsor
- Corin
Degenerative Disc Disease, Spondylolisthesis, Grade 1
AccuLIF® PROSPECTIVE PATIENT OUTCOMES STUDY
This is a post-market clinical study of the AccuLIF expandable transforaminal lumbar interbody fusion (TLIF) cage in patients requiring surgery for degenerative disc disease (DDD) with up to Grade I spondylolisthesis or…
- Conditions
- Degenerative Disc Disease, Spondylolisthesis, Grade 1, Retrolisthesis
- Trial name
- APROPOS (NCT02704689)
- Testing
- AccuLIF expandable TLIF cage
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- VB Spine, LLC
Bone Cysts, Bone Atrophy
Gene-activated Bone Substitute for Maxillofacial Bone Regeneration
The purpose of this study is to evaluate the safety and efficacy of the gene-activated bone substitute consisting of octacalcium phosphate and plasmid DNA encoding vascular endothelial growth factor (VEGF) for maxillofacial bone…
- Conditions
- Bone Cysts, Bone Atrophy, Bone Deformity, Bone Fracture
- Trial name
- NCT03076138
- Testing
- Gene-activated matrix (OCP + plasmid DNA with VEGF gene)
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Histograft Co., Ltd.
Biliary Tract Cancer, Cholangiocarcinoma
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
Study consisted of an open-label, safety run-in part and a randomized, double-blind, placebo-controlled Phase 2/3 part. In the Phase 2/3 part, the study was evaluated whether bintrafusp alfa in combination with the current…
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT04066491
- Testing
- M7824, Gemcitabine, Cisplatin
- Where
- 99 sites in United States, Argentina and 13 more
- Volunteers
- 309 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Moderate to Severe Rheumatoid Arthritis
A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
This study will compare the retention rates for UPA vs. TNFi treatment in adult participants with moderate to severe active RA per local label and according to local standard of care This is a mono-country, prospective…
- Trial name
- UP-RISING (NCT06712628)
- Where
- 75 sites in Germany
- Volunteers
- 678 people
- Sponsor
- AbbVie
Metastatic Soft-Tissue Sarcomas, Metastatic Bone Sarcomas
Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)
The purpose of this study is to determine whether maintenance therapy with oral AP23573 (ridaforolimus), by preventing and controlling tumor growth for a prolonged period of time in patients with metastatic soft-tissue or bone…
- Trial name
- SUCCEED (NCT00538239)
- Testing
- ridaforolimus
- Volunteers
- 711 people
- Sponsor
- Merck Sharp & Dohme LLC
Embolization, Vascular Tumor
Evaluation of a Simple-Prep Controlled Embolic
The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in…
- Conditions
- Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma
- Trial name
- GPX (NCT06453642)
- Testing
- GPX® Embolic Device
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 114 people
- Sponsor
- Fluidx Medical Technology, Inc.
Neuroma
ALGRX 4975 in the Treatment of Patients With Morton's Neuroma
Subjects will have painful primary or post-operative intermetatarsal neuroma. Study drug or placebo will be injected into the space containing the neuroma.
- Trial name
- NCT00130962
- Testing
- ALGRX 4975
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- AlgoRx Pharmaceuticals
Rheumatoid Arthritis
Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia
An observational study assessing the impact of anti-citrullinated antibody (ACPA) in rheumatoid arthritis (RA) participants who have received abatacept or tumour necrosis factor inhibitors (TNFi) from the Optimising Patient…
- Trial name
- NCT03663829
- Testing
- Non-Interventional
- Where
- Australia
- Volunteers
- 2,052 people
- Sponsor
- Bristol-Myers Squibb
Moderate and Severe Rheumatoid Arthritis
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
This is a phase Ⅱ, placebo-controlled, multicenter, dynamic randomized, double blind study of the efficacy and safety of RC18, a recombinant human B lymphocyte stimulating factor receptor-antibody fusion protein in subjects with…
- Trial name
- NCT02882087
- Testing
- RC18 160 mg plus MTX
- Where
- China
- Volunteers
- 60 people
- Sponsor
- RemeGen Co., Ltd.
Bone Cancer, Bone Tumor
A Dose Finding Study to Treat Bone Tumor(s)
To determine the Maximum Tolerated Dose (MTD) of CycloSam®, Samarium-153-DOTMP (Sm-153-DOTMP), a radiopharmaceutical that delivers radiation to the bone when injected, given as a tandemly administered pair of doses to subjects…
- Conditions
- Bone Cancer, Bone Tumor, Solid Tumor, Metastatic Cancer to the Bone
- Trial name
- NCT06008483
- Testing
- 153-Sm-DOTMP (Samarium-153-DOTMP)
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- QSAM Therapeutics, Inc.
Rheumatoid Arthritis
A Study to Determine the Number of Participants With Rheumatoid Arthritis (RA) Who Meet the Requirements for Treatment With Anti-Tumor Necrosis Factor α (TNFα) in a General Hospital Setting in Korea
This is an observational study to estimate the proportion of patients diagnosed with RA visiting a medical internist in a general hospital in Korea who are candidates for anti-TNF α therapy.
- Trial name
- NCT01294722
- Where
- South Korea
- Volunteers
- 1,700 people
- Sponsor
- Janssen Korea, Ltd., Korea
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors.
- Trial name
- FLAGSHP-1 (NCT04670679)
- Testing
- ERAS-601, Cetuximab, Pembrolizumab
- Where
- 14 sites in United States, Australia
- Volunteers
- 90 people
- Sponsor
- Erasca, Inc.
Rheumatoid Arthritis
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy
The primary objective is to compare the safety and efficacy of multiple doses of ABT-494 versus placebo in moderately to severely active RA subjects on stable background MTX therapy with inadequate response or intolerance to…
- Trial name
- NCT01960855
- Testing
- ABT-494
- Volunteers
- 276 people
- Sponsor
- AbbVie
Spine Fracture, Degenerative Disc Disease
Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Cervical
Multicenter Post market clinical follow-up Study on the Safety and Performance of Ennovate® Cervical - Prospective, pure data collection of all Ennovate Cervical patients in Total Indications
- Conditions
- Spine Fracture, Degenerative Disc Disease, Spinal Instability, Spinal Tumor
- Trial name
- CERISE (NCT05296889)
- Testing
- posterior stabilization for the cervical spine
- Where
- 4 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Aesculap AG
Ewing Sarcoma, Solid Tumors
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults…
- Conditions
- Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma
- Trial name
- NCT03709680
- Testing
- Palbociclib, Temozolomide, Irinotecan
- Where
- 84 sites in United States, Brazil and 11 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Biliary Tract Cancer, Cholangiocarcinoma
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
The study to evaluate M7824 monotherapy in participants with advanced or metastatic biliary tract cancer (BTC) who failed or were intolerant to first-line (1L) chemotherapy.
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT03833661
- Testing
- M7824
- Where
- 33 sites in United States, China and 7 more
- Volunteers
- 159 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Dupuytren's Contracture
Administration of Two Injections for Multiple Dupuytren's Contractures
The objectives of this study are to assess the safety and efficacy of concurrent administration of two injections of AA4500 into the same hand of subjects with multiple Dupuytren's contractures caused by palpable cords.
- Trial name
- NCT01407068
- Testing
- AA4500 collagenase clostridium histolyticum
- Where
- 8 sites in United States, Australia
- Volunteers
- 60 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Psoriasis
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
The main objective of this study is to evaluate the long term safety of CP-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis.
- Trial name
- NCT01519089
- Testing
- CP-690,550, CP-690, 550
- Where
- 16 sites in Japan
- Volunteers
- 95 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors
This prospective, post marketing, observational, Noninterventional Study (NIS) is designed to compare drug persistence in patients treated with Certolizumab Pegol (CZP) and patients treated with any other subcutaneously (sc)…
- Trial name
- NexT (NCT01764321)
- Where
- 122 sites in Germany
- Volunteers
- 1,723 people
- Sponsor
- UCB Pharma SA